The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults ... new major depression treatment to win FDA approval in more than three decades.

On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common ...

The FDA has approved Neffy, a needle-free nasal spray, for children aged 4 and up, providing fast and effective treatment for ...

Johnson & Johnson has won Food and Drug Administration expanded approval of its Spravato nasal spray as a lone therapy ... two oral antidepressants. The FDA in 2019 approved Spravato, a close ...

Johnson & Johnson's Spravato has been approved ... the need for daily oral antidepressants," Martin added. The FDA approval of Spravato comes after a controlled study showed the nasal spray provided ...

The FDA has approved neffy 1 mg epinephrine nasal spray for treating anaphylaxis and other type 1 allergic reactions in ...

Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 ...

The Food and Drug Administration (FDA) recently expanded approval for Spravato, an antidepressant nasal spray used to treat depression. Parkside Psychiatric Hospital has a Spravato outpatient ...

Neffy 1 mg is the “first significant innovation” for epinephrine delivery in small children aged 4 years and up in over 35 ...

FDA approves Neffy 1 mg for children aged 4+ weighing 15 to <30 kg for allergic reactions. Most insured patients can access Neffy for $25, while cash price is $199 for two doses. Our government tr ...

The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults ... new major depression treatment to win FDA approval in more than three decades.